Drugs Made In America Acquisition (DMIIR) Net Income towards Common Stockholders (2025)

Drugs Made In America Acquisition (DMIIR) reported Net Income towards Common Stockholders of $2.3 million for Q4 2025, up 28302.08% on a QoQ basis from -$8207.0 in Q3 2025.

Drugs Made In America Acquisition (DMIIR) has 1 years of Net Income towards Common Stockholders data on file, last reported at $2.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 3.12 Mn
2 Berto Acquisition 316.66 Mn 316.66 Mn - 443,750.00
3 Centurion Acquisition 311.94 Mn 311.94 Mn - 2.02 Mn
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - 1.49 Mn
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - -612,993.00
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - 465,276.00
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - 382,994.00
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - 1.34 Mn
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - 1.60 Mn
10 Drugs Made In America Acquisition - - - 2.31 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 2.31 Mn
Sep 30, 2025 -8,207.00